Abstract
Summary
Idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis, IPF) is a rare, chronic, and fatal disease that will gradually develop over a period of several years. It is typically characterized by the formation of scar tissue in the lungs and progressive dyspnea. It is the most common type of interstitial lung disease in idiopathic interstitial pneumonia. Its clinical features include shortness of breath, diffuse lung infiltrates on imaging, and lung biopsy showing varying degrees of inflammation/fibrosis or Both.
LPI (LP Information)' newest research report, the “Idiopathic Pulmonary Fibrosis Disease Treatment Industry Forecast” looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis Disease Treatment sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Pulmonary Fibrosis Disease Treatment industry.
This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Idiopathic Pulmonary Fibrosis Disease Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis Disease Treatment.
The global Idiopathic Pulmonary Fibrosis Disease Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Idiopathic Pulmonary Fibrosis Disease Treatment players cover Boehringer Ingelheim, Merck and Co., Inc., ArkBio, Zelgen, Blade Therapeutics, Regend Therapeutics (Cayman) Ltd., Insilico Medicine, Vicore Pharma and Heilongjiang Zbd Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis Disease Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pirfenidone
Nintedanib
Other
Segmentation by application
Hospital
Graduate School
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim
Merck and Co., Inc.
ArkBio
Zelgen
Blade Therapeutics
Regend Therapeutics (Cayman) Ltd.
Insilico Medicine
Vicore Pharma
Heilongjiang Zbd Pharmaceutical
Indaco
InterMune, Inc.
Bristol Myers Squibb
SHIONOGI & CO., Ltd.
LPI (LP Information)' newest research report, the “Idiopathic Pulmonary Fibrosis Disease Treatment Industry Forecast” looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis Disease Treatment sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Pulmonary Fibrosis Disease Treatment industry.
This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Idiopathic Pulmonary Fibrosis Disease Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis Disease Treatment.
The global Idiopathic Pulmonary Fibrosis Disease Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Idiopathic Pulmonary Fibrosis Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Idiopathic Pulmonary Fibrosis Disease Treatment players cover Boehringer Ingelheim, Merck and Co., Inc., ArkBio, Zelgen, Blade Therapeutics, Regend Therapeutics (Cayman) Ltd., Insilico Medicine, Vicore Pharma and Heilongjiang Zbd Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis Disease Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pirfenidone
Nintedanib
Other
Segmentation by application
Hospital
Graduate School
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim
Merck and Co., Inc.
ArkBio
Zelgen
Blade Therapeutics
Regend Therapeutics (Cayman) Ltd.
Insilico Medicine
Vicore Pharma
Heilongjiang Zbd Pharmaceutical
Indaco
InterMune, Inc.
Bristol Myers Squibb
SHIONOGI & CO., Ltd.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size 2018-2029
2.1.2 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Type
2.2.1 Pirfenidone
2.2.2 Nintedanib
2.2.3 Other
2.3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type
2.3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Type (2018-2023)
2.4 Idiopathic Pulmonary Fibrosis Disease Treatment Segment by Application
2.4.1 Hospital
2.4.2 Graduate School
2.4.3 Others
2.5 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application
2.5.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Application (2018-2023)
3 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Player
3.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Market Share by Players
3.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue by Players (2018-2023)
3.1.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Idiopathic Pulmonary Fibrosis Disease Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Idiopathic Pulmonary Fibrosis Disease Treatment by Regions
4.1 Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Regions (2018-2023)
4.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
4.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
4.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
4.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size Growth (2018-2023)
5 Americas
5.1 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Country (2018-2023)
5.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
5.3 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Region (2018-2023)
6.2 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
6.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Disease Treatment by Country (2018-2023)
7.2 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
7.3 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment by Region (2018-2023)
8.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Type (2018-2023)
8.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Regions (2024-2029)
10.1.1 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Regions (2024-2029)
10.1.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.1.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.1.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.1.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Forecast
10.2 Americas Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Country (2024-2029)
10.2.1 United States Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.2.2 Canada Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.2.3 Mexico Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.2.4 Brazil Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3 APAC Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Region (2024-2029)
10.3.1 China Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.2 Japan Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.3 Korea Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.4 Southeast Asia Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.5 India Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.3.6 Australia Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4 Europe Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Country (2024-2029)
10.4.1 Germany Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.2 France Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.3 UK Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.4 Italy Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.4.5 Russia Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5 Middle East & Africa Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Region (2024-2029)
10.5.1 Egypt Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.2 South Africa Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.3 Israel Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.4 Turkey Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.5.5 GCC Countries Idiopathic Pulmonary Fibrosis Disease Treatment Market Forecast
10.6 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Type (2024-2029)
10.7 Global Idiopathic Pulmonary Fibrosis Disease Treatment Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Information
11.1.2 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.1.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Boehringer Ingelheim Main Business Overview
11.1.5 Boehringer Ingelheim Latest Developments
11.2 Merck and Co., Inc.
11.2.1 Merck and Co., Inc. Company Information
11.2.2 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.2.3 Merck and Co., Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Merck and Co., Inc. Main Business Overview
11.2.5 Merck and Co., Inc. Latest Developments
11.3 ArkBio
11.3.1 ArkBio Company Information
11.3.2 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.3.3 ArkBio Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 ArkBio Main Business Overview
11.3.5 ArkBio Latest Developments
11.4 Zelgen
11.4.1 Zelgen Company Information
11.4.2 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.4.3 Zelgen Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Zelgen Main Business Overview
11.4.5 Zelgen Latest Developments
11.5 Blade Therapeutics
11.5.1 Blade Therapeutics Company Information
11.5.2 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.5.3 Blade Therapeutics Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Blade Therapeutics Main Business Overview
11.5.5 Blade Therapeutics Latest Developments
11.6 Regend Therapeutics (Cayman) Ltd.
11.6.1 Regend Therapeutics (Cayman) Ltd. Company Information
11.6.2 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.6.3 Regend Therapeutics (Cayman) Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Regend Therapeutics (Cayman) Ltd. Main Business Overview
11.6.5 Regend Therapeutics (Cayman) Ltd. Latest Developments
11.7 Insilico Medicine
11.7.1 Insilico Medicine Company Information
11.7.2 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.7.3 Insilico Medicine Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Insilico Medicine Main Business Overview
11.7.5 Insilico Medicine Latest Developments
11.8 Vicore Pharma
11.8.1 Vicore Pharma Company Information
11.8.2 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.8.3 Vicore Pharma Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Vicore Pharma Main Business Overview
11.8.5 Vicore Pharma Latest Developments
11.9 Heilongjiang Zbd Pharmaceutical
11.9.1 Heilongjiang Zbd Pharmaceutical Company Information
11.9.2 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.9.3 Heilongjiang Zbd Pharmaceutical Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Heilongjiang Zbd Pharmaceutical Main Business Overview
11.9.5 Heilongjiang Zbd Pharmaceutical Latest Developments
11.10 Indaco
11.10.1 Indaco Company Information
11.10.2 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.10.3 Indaco Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Indaco Main Business Overview
11.10.5 Indaco Latest Developments
11.11 InterMune, Inc.
11.11.1 InterMune, Inc. Company Information
11.11.2 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.11.3 InterMune, Inc. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 InterMune, Inc. Main Business Overview
11.11.5 InterMune, Inc. Latest Developments
11.12 Bristol Myers Squibb
11.12.1 Bristol Myers Squibb Company Information
11.12.2 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.12.3 Bristol Myers Squibb Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Bristol Myers Squibb Main Business Overview
11.12.5 Bristol Myers Squibb Latest Developments
11.13 SHIONOGI & CO., Ltd.
11.13.1 SHIONOGI & CO., Ltd. Company Information
11.13.2 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Product Offered
11.13.3 SHIONOGI & CO., Ltd. Idiopathic Pulmonary Fibrosis Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 SHIONOGI & CO., Ltd. Main Business Overview
11.13.5 SHIONOGI & CO., Ltd. Latest Developments
12 Research Findings and Conclusion